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Abstract
In conducting studies on an exposure of interest, a systematic roadmap should be applied for 
translating causal questions into statistical analyses and interpreting the results. In this paper we 
describe an application of one such roadmap applied to estimating the joint effect of both time to 
availability of a nurse-based triage system (low risk express care (LREC)) and individual 
enrollment in the program among HIV patients in East Africa. Our study population is comprised 
of 16,513 subjects found eligible for this task-shifting program within 15 clinics in Kenya between 
2006 and 2009, with each clinic starting the LREC program between 2007 and 2008. After 
discretizing follow-up into 90-day time intervals, we targeted the population mean counterfactual 
outcome (i. e. counterfactual probability of either dying or being lost to follow up) at up to 450 
days after initial LREC eligibility under three fixed treatment interventions. These were (i) under 
no program availability during the entire follow-up, (ii) under immediate program availability at 
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initial eligibility, but non-enrollment during the entire follow-up, and (iii) under immediate 
program availability and enrollment at initial eligibility. We further estimated the controlled direct 
effect of immediate program availability compared to no program availability, under a hypothetical 
intervention to prevent individual enrollment in the program. Targeted minimum loss-based 
estimation was used to estimate the mean outcome, while Super Learning was implemented to 
estimate the required nuisance parameters. Analyses were conducted with the ltmle R package; 
analysis code is available at an online repository as an R package. Results showed that at 450 days, 
the probability of in-care survival for subjects with immediate availability and enrollment was 0.93 
(95% CI: 0.91, 0.95) and 0.87 (95% CI: 0.86, 0.87) for subjects with immediate availability never 
enrolling. For subjects without LREC availability, it was 0.91 (95% CI: 0.90, 0.92). Immediate 
program availability without individual enrollment, compared to no program availability, was 
estimated to slightly albeit significantly decrease survival by 4% (95% CI 0.03,0.06, p<0.01). 
Immediately availability and enrollment resulted in a 7 % higher in-care survival compared to 
immediate availability with non-enrollment after 450 days (95% CI−0.08,−0.05, p<0.01). The 
results are consistent with a fairly small impact of both availability and enrollment in the LREC 
program on incare survival.
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1 Introduction
van der Laan and Rose (2011), Petersen and van der Laan (2014), Pearl (2009) and others 
have advocated for the use of a systematic road map for translating causal questions into 
statistical analyses and interpreting the results. This road map requires the analyst to learn as 
much as possible about how the data were generated, posit a realistic statistical model that 
encompasses these findings, and assign a corresponding estimand that can answer the 
scientific question of interest. While in some cases this approach can be straightforward, in 
practice it generally requires much consideration when implementing. This is especially true 
in observational data, where a common objective is to estimate the joint effect of one or 
more longitudinal exposures, or a series of sequential treatment decisions (e. g. Bodnar 
2004; Bryan 2004; Petersen et al. 2014). For example, one may be interested in contrasting 
immediate enrollment into a particular program (a single treatment decision) with delayed 
enrollment (a series of treatment decisions, in which enrollment is sequentially deferred at 
multiple time points at which it could have been initiated).
It is well recognized that the cumulative effect of such longitudinal exposures is often 
subject to time dependent confounding (e. g. Robins et al. 2000a; Bodnar 2004). For 
example, the decision to continue to defer enrollment at post-baseline time points may be 
affected by covariates that affect the outcome (and are thus confounders), and that are 
themselves affected by the prior decision not to enroll. If not properly accounted for, the 
resulting estimates may be biased for the parameter of interest.
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Similar challenges arise in analyses aiming to estimate the effect of one longitudinal 
exposure while holding a second longitudinal exposure constant. For example, how would 
patient outcomes have differed under immediate versus deferred exposure to a clinic level 
intervention, if individual level enrollment were prevented? Such a controlled direct effect of 
two longitudinal exposures can be used to investigate the mechanisms by which an exposure 
is mediated by individual level uptake. In such scenarios, both longitudinal exposures may 
be subject to time dependent confounding.
Using the counterfactual framework, Robins (1986) and Robins et al. (1999) showed that 
both longitudinal effects and controlled direct effects can be identified in the presence of 
time dependent confounding. A range of estimators of such effects (or more precisely, 
estimators of the statistical estimands to which the counterfactual effects correspond under 
the sequential randomization assumption), have been developed, implemented, and applied 
(e. g. Robins 1987; Robins et al. 1999; Robins and Herná 2009; Hernán and Robins 2006; 
Pearl 2009). Prominent examples include inverse probability weighted (IPW) (Horvitz and 
Thompson 1952; Koul et al. 1981; Robins and Rotnitzky 1992; Satten and Datta 2001, 2004; 
Rotnitzky and Robins 2005; Hernán and Robins 2006), parametric g-computation (Robins et 
al. 1999; Robins and Hernán 2009; Hernán and Robins 2006; Taubman et al. 2009), and 
double robust estimating equation-based estimators (Robins et al. 2000b; van der Laan and 
Robins 2003; Bang and Robins 2005; Tsiatis 2006). More recently, Bang and Robins (2005) 
also introduced iterated conditional expectation g-computation and double robust 
substitution estimators, which van der Laan and Gruber (van der Laan and Gruber 2011) 
placed within the general targeted minimum loss-based estimation (TMLE) framework (van 
der Laan and Rubin 2006).
The TMLE (Bang and Robins 2005; van der Laan and Gruber 2011) offers a number of 
advantages, as have been reviewed elsewhere (van der Laan and Gruber 2011; van der Laan 
and Rose 2011). In particular, the TMLE does not suffer to the same extent from positivity 
violations (Hernán and Robins 2006; Westreich and Cole 2010) as IPW (Petersen et al. 
2012), and allows for full integration of machine learning while retaining valid inference 
(van der Laan and Rose 2011; Brooks et al. 2013; Schnitzer et al. 2014 Decker et al. 2014). 
In this paper we describe an application of this methodology to estimate the joint effect of 
both time to program availability and individual enrollment in a task shifting program 
among HIV patients in East Africa. We provide a detailed description of this analysis, with 
an emphasis on several practical challenges likely to arise in similar applications. In doing 
so, we perform a case study of the targeted learning road map in the longitudinal setting (van 
der Laan and Rose 2011; Petersen and van der Laan 2014; Petersen 2014). In particular, we 
emphasize two primary issues. The first is the translation of the scientific questions into 
counterfactual causal parameters, including a total effect and controlled direct effect. The 
hypothetical interventions for comparison are carefully defined to avoid known and potential 
positivity violations. The second is the use of recently developed estimation methods, 
including a double robust and semiparametric efficient targeted minimum loss-based 
estimator that integrates Super Learning for nuisance parameter estimation (van der Laan et 
al. 2007), and the imposition of global restraints for conditional distributions implied by our 
statistical model. We discuss several decisions and practical challenges that arise as a result, 
and provide corresponding R code.
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The paper is organized as follows. In Section 2, we provide brief background on the 
scientific question of interest as well as review the targeted learning road map. In Section 3, 
we present the data as measured and formalized into a statistical framework. Section 4 posits 
the causal model for the data, while Section 5 addresses the target parameter, positivity 
violations, and identifiability. Section 6 focuses on estimating both the target and nuisance 
parameters. Section 7 presents the results of our approach, while Section 8 closes with a 
discussion and areas of future research.
2 Background
The majority of individuals with HIV live in settings, such as East Africa, where noticeable 
resource and infrastructure constraints place a limitation on the care these patients can 
receive (Stringer et al. 2006; World Health Organization 2013a). Antiretroviral therapy 
(ART) medication has been shown to reduce both viral loads and mortality in these patients 
(Gulick et al. 1997; Palella et al. 1998; Zwahlen et al. 2009; Dieffenbach and Fauci 2011; 
Danel et al. 2015; Lundgren et al. 2015), as well as reduce rates of transmission to persons 
uninfected (Quinn et al. 2000; Attia et al. 2009; Das et al. 2010; Cohen et al. 2011). 
However, the shortage of resources and health care professionals limit the number of 
patients who can be placed on ART (Van Damme et al. 2006; Koole and Colebunders 2010; 
World Health Organization 2013b; UNAIDS 2013).
Due to these limitations, various approaches have been undertaken in an effort to ensure that 
the maximal number of patients who need care can receive it. One such approach shifts care 
provision tasks for patients considered to be at low risk from physicians and clinical officers 
to other care professionals, such as nurses. Consequently, the workload for the physicians 
and clinical officers is reduced, theoretically increasing the attention that higher risk patients 
can receive for HIV or other conditions (World Health Organization 2013a).
One such program was implemented between 2007 and 2009 among clinics around eastern 
Africa. These clinics were followed as part of the Academic Model Providing Access to 
Healthcare (AMPATH) program, and contributed data to the International epidemiologic 
Databases to Evaluate AIDS, East Africa region (IeDEA-EA). The purpose of this Low Risk 
Express Care (LREC) program is to shift care tasks for patients considered to be at low risk 
from physician-centered care models to those utilizing non-physician health workers trained 
in simplified and standardized approaches to care. Patients were considered to be at low risk 
if they met the following set of criteria.
1. They were older than 18 years of age.
2. They were stable on ART for at least 6-months.
3. They had no AIDS-defining or AIDS-associated events within the past 180-days.
4. During past 6 months, they reported no missed pills when asked about the 7 days 
prior to each visit.
5. They were not pregnant within the past 30 days.
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6. Their most recent CD4 count >200 cells/μL within 274 days prior to the current 
visit.
Once eligible, at each clinical visit, the clinician decided whether or not to enroll the patient 
into the LREC program. Patients enrolled had part of their care, such as identifying and 
managing ART side effects and opportunistic infections, shifted to nurses. Table 1 shows the 
differences between the standard of care and the LREC model.
In implementing this task-shifting program, a primary question of interest among health care 
providers is whether (i) clinic level exposure to and (ii) individual level enrollment in the 
program results in either better or worse clinical outcomes. For example, it could be that 
enrollment in the program increases loss to follow up and mortality because care is received 
from individuals who have a lower level of qualification/certification. Alternatively, 
enrollment in the program might decrease mortality and loss to follow-up due to more 
attentive and personal care given to enrolled patients. It could also be that an equivalent level 
of care is provided and thus, no impact is observed. Furthermore, receiving care at a clinic 
that has already implemented the LREC program might itself have a direct beneficial or 
detrimental effect on patient outcomes, in addition to an indirect effect mediated by patient 
enrollment in the program. Such an effect could result, for example, from changes in clinic 
practices made possible by shifts in workload.
2.1 Causal inference road map
We follow the targeted learning road map as presented by van der Laan and Rose (2011) and 
Petersen and van der Laan (2014). We briefly summarize the road map for longitudinal static 
interventions and corresponding notation below, and refer readers interested in further 
details to the cited articles.
Any causal scientific question must first be framed as a statistical question that can be 
answered with the observed data. Defining a statistical question includes properly defining 
the data, statistical model, and estimand or statistical parameter of interest. Here we consider 
data that consist of n independent and identically distributed observations of a random 
(vector) variable o with some underlying probability distribution P0. The statistical model 
 should be chosen to ensure that it contains the true distribution P0, and thus any model 
assumptions should be based only on real knowledge about the process that generated the 
data. In practice this generally implies a semiparametric or nonparametric statistical model.
Translating causal questions into such a statistical estimation problem requires translating 
the scientific question into a formal causal query. This is typically defined as a parameter of 
the counterfactual distribution. We consider counterfactual experiments indexed by static 
interventions to set a vector Ā of treatment or exposure variables equal to a set value ā, and 
denote the resulting counterfactual distribution . The statistical mode  can then be 
modified to incorporate non-testable causal assumptions about the data generating process. 
These causal assumptions are representable using structural causal diagrams or structural 
equation models (Pearl 2009). The resulting causal model  is a model on  under each 
ā of interest.
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One must determine what additional causal assumptions (if any) are needed in order to 
identify the target causal parameter from the distribution of the observed data. In this paper, 
we focus on the estimand provided by Bang and Robins (2005) through the iterated 
conditional expectation representation of the longitudinal g-formula. This parameter 
identifies the causal effects of longitudinal interventions under the sequential randomization 
and positivity assumptions.
Once identifiability has been established, the statistical model  and target parameter of the 
observed data distribution P0 to the real line are used to select a corresponding estimator 
which is a function of the empirical distribution of the observed data Pn. This process may 
additionally require nuisance parameter estimation. Here, we describe implementation of a 
double robust efficient targeted maximum likelihood estimator (Bang and Robins 2005). The 
resulting  is used in calculating the parameter estimate  Corresponding standard 
errors for the estimates are calculated based on the estimated influence curve and results are 
then interpreted. In the following sections we illustrate each of these steps in greater detail 
using the LREC analysis as a case study.
3 Data
Our study population is comprised of subjects found eligible for the LREC program within 
each of 15 clinics in Kenya between 2006 and 2009, with each clinic starting the LREC 
program between 2007 and 2008. Table 2 shows the characteristics of the 15 clinics.
In an effort to ensure that other unmeasured (or unmeasurable) aspects of care remained 
roughly constant, the first point of patient eligibility was truncated at 1-year prior to LREC 
program initiation at each clinic. Our target population is therefore comprised of patients 
found eligible for LREC within 1-year before the clinic’s start date up to the administrative 
censoring date (5 March 2009). Our baseline timepoint (t=0) was defined to be the first date 
at which a patient was eligible for the program within this window. Figure 1 shows the 
distribution of the time from baseline to start of the LREC program. Subjects becoming 
eligible post LREC program initiation were assigned a time of o. A small number of subjects 
had more than one year of follow up from baseline to LREC program initiation as a result of 
transferring to a new clinic with a later LREC start date. As patients generally visited clinics 
every three months, we discretized follow-up into time intervals of 90 days.
Patients were followed from the baseline time point defined above until one of four possible 
end points:
1. Death
2. Loss to follow-up (LTFU), defined here to be 198 days with no clinical visits
3. Database closure, occurring on 5 March 2009
4. Transfer to a clinic with no LREC program
For the present study, we were interested in the effect of LREC exposure and enrollment on 
the probability of remaining alive and in clinical care. In settings such as these, no standard 
national death registry exists. Consequently, relying solely on observed mortality would 
Tran et al. Page 6
Epidemiol Methods. Author manuscript; available in PMC 2017 July 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
undercount the risk of death in our study population. Further, past research in this setting has 
found that a major reason (although certainly not the only reason) for apparent LTFU is 
unreported death (Geng et al. 2015, 2016). For example, a recent study by Geng et al. (2016) 
found that over 30% of subjects classified lost to follow up were unreported deaths. Without 
supplemental data, such unreported deaths preclude identification of causal parameters that 
treat death as the outcome and censor at LTFU, as well as parameters that treat LTFU as the 
outcome and censor at death (Geng et al. 2012). Furthermore, patients who do not return for 
continuing HIV care are subject to higher risk of complications and health decline 
(Kissinger et al. 1995; Samet et al. 2003; Giordano et al. 2005, 2007; Horstmann et al. 
2010), placing them at unnecessarily higher mortality rates. We therefore define our 
outcome of interest as a composite of either the occurrence of death or LTFU. Patients were 
followed until this “failure” or until censoring due to either end of study or transfer. We 
aimed to evaluate the impact of (a) implementation of the LREC program at the clinic, and 
(b) enrollment into the LREC program after implementation on both retention “in-care” and 
survival.
3.1 Observed data
For notational convenience, we defined variables after the occurrence of any of these end 
points as equal to their last observed value. Following discretization of the data, we have a 
longitudinal data set with time-varying covariates, where the time points t correspond to 90-
day intervals (e. g. 0, 90, 180,… days). Let W be the observed baseline time-independent 
covariates observed at the date the patient was first eligible for LREC (age at eligibility, CD4 
count at start of ART, gender, indicator that ART regimen is protease-inhibitor based at 
eligibility, treated for tuberculosis at start of ART, indicator at urban clinic at eligibility, and 
WHO immunologic stage at both the start of ART and maximum stage prior to start). Let the 
time-varying variables from the observed data for each time point t be:
[1]
Where
– L1(t) consists of the most recent measures of time-varying covariate values at 
the start of interval t, inclusive of covariates measured at the clinic level (i. e. 
calendar date, most recent, nadir, and zenith CD4 count, days since enrolling 
into the AMPATH program, an indicator of remaining on ART, pregnancy status, 
indicator in WHO stage III or IV, indicator of being treated for tuberculosis, 
clinic type (rural or urban), and an indicator of having at least one clinic visit in 
the previous interval).
– Y(t) is an indicator that the patient is either (a) no longer in care (not seen in the 
clinic for 198 days) or (b) has died by the end of interval t. It jumps to and 
remains at 1 if either event occurs.
– A1(t) is an indicator of the LREC program availability by the end of interval t. It 
jumps to and remains at 1 once the program has started.
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– A2(t) is an indicator of enrollment into the LREC program by the end of the 
interval. It jumps to and remains at 1 at time of enrollment and remains at 0 if 
A1(t)=0.
– C1(t) is an indicator that the patient transfers by the end of interval t to a clinic 
other than one of the 15 clinics that initiate the LREC program. It also jumps to 
and remains at 1 once the patient transfers.
– C2(t) is an indicator of data base closure by the end of interval t. It jumps to and 
remains at 1 at the end of the study. Note that although database closure occurs 
at a fixed calender date, censoring time due to database closure remains a 
random variable due to variability in time of eligibility for LREC.
We refer to the covariate and outcome nodes collectively as L(t)=(L1(t), Y(t)) and the 
treatment and censoring processes together as A(t)=(A1(t), A2(t), C1(t), C2(t)). Our 
observable data for each subject i can therefore be expressed as
[2]
where L(0) include our baseline variables W and K+1 is our final time point of interest, here 
equal to 4. We assume the observed data over all subjects consists of n copies of , 
where P0 is the true underlying distribution.
4 Causal model
A causal model allows us to represent additional knowledge and assumptions associated 
with our scientific question that cannot be represented statistically. We present our causal 
model  by making use of structural equation models to formally present how we assume 
each variable to be generated. We use a causal model that treats the 15 clinics as fixed, rather 
than sampled, and which describes an experiment in which individual subjects become 
eligible for LREC at random times. Specifically, we define the following non-parametric 
structural equation model (NPSEM) (Pearl 2009) to represent our knowledge about the 
causal process that generated the observed data.
[3]
where U=(UL1(t), UY(t), UA1(t), UA2(t), UC1(t), UC2(t)) are unmeasured exogenous variables 
from some underlying probability distribution PU (assumed to satisfy the back door criterion 
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(Pearl 2009) as detailed in Section 5.1.1) and L(−1)=A(−1)=Ø. For notational convenience, 
we define t−=t−1 and define  to denote the history of variable 
X up to time t.
This causal model specifies how we believe each of the variables in our data are 
deterministically generated, with randomness coming only from the unmeasured exogenous 
variables U. It tells us, for example, that individual enrollment immediately following LREC 
eligibility A2(0) is generated as a deterministic function fA2(0) of L(0), program availability 
A1(0), and an error term UA2(0) drawn from some underlying population. Additionally, 
while not explicitly stated in eq. [3], we note that the deterministic function for enrollment 
fA2(t) sets A2(t)=0 with probability 1 if Ā1(t)=1, i. e. if the program is not yet available.
Note that censoring due to end of study C2(t) is not a function of time updated covariates 
 beyond baseline covariates L(0). This is because, while the values of L(0) may vary due 
to the calender date at which a subject’s baseline eligibility occurs, once this date is set for a 
given subject, the censoring process due to database closure is deterministic.
Our outcome Y(t) is assumed to be a function of treatment and censoring A(t) only up to the 
previous time point, t−1. This restriction is imposed in order to preserve causal ordering, 
since death/LTFU (Y(t)) in an interval t clearly affects enrollment (A(t)) in the same interval. 
Consequently, the effects of availability and enrollment within an interval on the composite 
outcome are only captured beginning in the following interval.
5 Target parameter
In this framework, t=1 is the first time point at which treatment assignment a(t) could affect 
survival. As the purpose of this study is to analyze the impact of different levels of treatment 
on the outcome, we conditioned on survival past t=0. Thus, we had that Y(0)=0 for all 
subjects included in the study. That is, all subjects in the study survived past the first 90 
days.
Conceptualizing an ideal hypothetical experiment can help in defining the target 
counterfactual parameter of interest. In order to evaluate the effect of exposure to and 
enrollment in the LREC program, we can conceive of an experiment in which we compare 
survival over time under alternative interventions to set time to program availability, time to 
enrollment following availability, and under an additional intervention to prevent censoring. 
As represented above in the causal model, these counterfactual outcome distributions are 
defined in terms of an intervention on the data-generating mechanism for A(t): t=0,1, …,K. 
In other words, we intervene to set values of program availability, enrollment, and censoring 
to some fixed values of interest at all time points.
Recall that our interest is evaluating both the total effect of exposure to the LREC program, 
and the direct effect of this exposure not mediated by individual level enrollment. Let 
denote the counterfactual outcome process up to time t* under an intervention to set both 
time of program availability (ā1) and time of individual enrollment (ā2). Our target 
parameter for a given intervention of interest is  where  is the 
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cumulative counterfactual probability of failure by time t* under intervention ā. As we have 
conditioned on surviving past t=0 (the first 90-days of follow-up), our range represents the 
cumulative probability of failure between 91 and 450 days post-eligibility.
When contrasting counterfactual failure probabilities under distinct interventions, we 
focused on estimating the absolute risk difference (or average treatment effect). Specifically, 
we contrasted these counterfactual survival probabilities under the three following 
interventions: Our first intervention assigns all patients to have no program availability at all 
time points (set A1(t)=A2(t)=0: t=1,2, …,K), and forces patients to remain uncensored (set 
C1(t)=C2(t)=0: t=1,2, …,K). The corresponding 4 counterfactual survival probabilities 
 give us an understanding of survival patterns without the LREC 
program.
The second intervention of interest is to assign all patients to have immediate program 
availability (set A1(t)=1: t=1,2,, K), but not allow any subjects to enroll into the program (set 
A2(t)=0: t=1,2, …, K). Patients would again be forced to remain uncensored and the 
counterfactual survival probability at each time point  would be 
calculated. By evaluating  we target the 
controlled direct effect of exposure to the program if enrollment were prevented.
The third intervention is to assign all patients to have both immediate availability and 
enrollment (set A1(t)=A2(t)=1: t=1,2, …, K). Again, censoring would be prevented and the 
counterfactual survival probability at each time point  would be 
calculated. Evaluating  allows us to target the 
total effect of enrollment in a scenario where all subjects experienced immediate availability.
5.1 Identifiability
5.1.1 Sequential randomization—To establish identifiability of our causal parameter, 
we first make the assumption of sequential randomization. That is, we assume that
[4]
Informally, we assume that the measured covariates are sufficient to control for confounding 
of our treatment effect. Consequently, at any time point t the observed treatment is 
independent of the full data given the data observed up to time point t. This assumption is 
met when the exogenous variables U are drawn from PU such that the back door criterion is 
satisfied (Pearl 2009). Assuming that U are independent of each other and across time, for 
example, would satisfy the criterion. In this context, the major concern for violation of this 
assumption is that among patients classified as clinically stable, some patients are healthier 
or at lower risk of loss than others in ways not captured by the measured covariates, and 
these patients are differentially enrolled into the program.
5.1.2 Positivity—In addition, we assume that a subject had a positive probability of 
following each regime of interest (no availability, immediate availability and no enrollment, 
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and immediate availability and enrollment) at each time point, regardless of their observed 
past:
[5]
Patients losing their eligibility for the LREC program posed a particular threat to this 
assumption. Our study population is comprised of patients initially deemed eligible for the 
LREC program due to their low risk. However, a noticeable proportion of the study 
population (32%) lost their eligibility at some point during follow-up. Once these patients 
were ineligible, they had a near 0 probability of subsequent program enrollment. To 
circumvent this potential positivity violation, we considered only treatment interventions 
which avoided enrollment at these time points. For example, consideration of patients who 
enroll immediately into the program would not encounter this issue, as all patients are 
eligible at the start of follow-up. Consideration of patients never enrolling into the program 
is also valid, as patients who are not eligible do not enroll. We further note that patients who 
lost their eligibility after enrollment into the LREC program were still considered to be 
enrolled. Similarly, patients who transferred to a new clinic without availability after 
receiving care at a clinic where LREC was available were considered exposed to the LREC 
program (in other words, we conducted an intent to treat type analysis of the effect of both 
availability and enrollment).
Under the assumptions of positivity and sequential randomization, the g-formula (Robins 
1986, 1987) identifies the distribution that the observed data would have had under a 
counterfactual treatment, even when time-dependent confounders are present and are 
affected by prior components of the specified treatment. For our parameter, the standard g-
computation representation for our target parameter is
[6]
where the right hand side is a parameter of the observed data distribution P0. The g-
computation recursive algorithm for estimating the cumulative probability of failure, 
introduced by Robins (2000) and expanded in Bang and Robins (2005), calls upon the tower 
rule of conditional expectations for this identity, suggesting an iterative conditional 
expectation (ICE) approach to estimating our parameters. Using their results, our parameter 
can therefore instead be expressed as
[7]
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where Lā(t) is the variable L(t) from the post intervention distribution resulting from setting 
Ā(t−)=ā(t−) and the expectations are taken with respect to this distribution. Thus, given 
 is equivalent to conditioning on 
6 Estimation
The ICE approach has a number of advantages compared to the more simple standard g-
computation procedure. The most noticeable among them is that we are only required to 
estimate the iteratively defined conditional expectations as opposed to the entire conditional 
densities of the covariate process L(t). We therefore use the ICE approach here. A small 
disadvantage is that these set of regressions must be run separately for each desired 
treatment rule, ā, whereas the classical parametric g computation approach only has to 
estimate the conditional densities once. We note however that this is a very small price to 
pay when compared against the substantial gain achieved by not having to estimate the 
entire joint density, especially when dealing with high dimensional data.
While the ICE approach already provides a considerable advantage towards our estimation 
goals, using targeted minimum loss-based estimation (van der Laan and Gruber 2011; Bang 
and Robins 2005) provides a further gain. This approach provides a substitution estimator 
that solves the estimating equation corresponding to the efficient influence function D(P) for 
our estimand. This removes the bias associated with the untargeted minimization of a global 
loss function for the density of the data. It is also known to be double robust, in that 
consistent estimation of the target parameter is obtained if either of the treatment mechanism 
or the iterated conditional expectations are estimated consistently. This approach is 
guaranteed to respect the parameter constraints implied by our statistical model. An R 
package titled ltmle has been developed which implements this estimator (Lendle et al. 
2016; Petersen et al. 2013). This package takes longitudinal data supplied in wide format 
and estimates our target parameter for each specified treatment rule ā.
A number of options are available to users of the ltmle R package. For example, the 
probabilities of treatment and censoring A(t) at each time point (for the specified treatment 
rule ā) can be separately estimated and subsequently fed into the estimation procedure, 
rather then being fit within. This allows the analyst the option of pooling the observations 
over all time points and estimating probabilities within this pooled sample, as opposed to 
fitting separate models for each time point. Doing so provides a lower variance in estimates 
of the treatment mechanisms at the cost of potentially higher bias.
An additional advantage of pooling over all observations in estimating our treatment and 
censoring mechanisms is that we can use additional data that is not included in modeling the 
ICEs. That is, data observed beyond the final time point t* can be used to aid in estimating 
the probabilities of treatment for A(t): t=0,1, …, t*−1. This can be advantageous and 
promotes stability in the estimates by borrowing information across all time points. 
Specifically, it helped in the present study in estimating our censoring from transfer 
mechanism, due to the extremely small number of transfers observed. For this study, we 
choose to pool across observations to fit the treatment mechanisms, though note that the 
decision between the two did not significantly affect the parameter estimates.
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An additional package option is the ability to pool over all subjects when estimating the 
ICEs irrespective of observed treatment, as opposed to stratifying the data and using only 
subjects following the treatment rule specified. This choice implies an analogous bias-
variance trade off. Pooling over subjects regardless of treatment history potentially allows 
for more stable estimates of the ICEs due to the lower variance. This option is helpful when 
the number of time points is large and the number of persons following a particular 
treatment regime over all time points is small.
Use of the ltmle R package requires that the data be provided in a wide format and with a 
time-ordering of the covariates. In doing so, two options are available for the L(t) node at 
each time point t, i. e. L1(t), Y(t) or Y(t),L1(t). In our causal model in Section 4, the L(t) 
node is not affected by the specified order. Therefore, use of either ordering will suffice in 
our study. We additionally note that even if the timeordering did matter and our outcome of 
interest Y(t*) were, say, dependent upon the covariates L1(t*), there is still no need to 
condition on L1(K + 1) for the sake of estimating our target parameter as the efficient 
influence function D(P) for our parameter based on the full data o is the same as the efficient 
influence function based on reduced data Or=o/L1(K + 1). We provide a short proof for this 
in the Appendix.
6.1 Super learning the nuisance parameters
Consistent, asymptotically linear, and efficient estimation of our target parameter requires 
that the treatment and censoring A(t) mechanisms as well as ICEs be estimated in a 
consistent manner and at a fast enough rate (van der Laan and Rose 2011). Using parametric 
models to do this requires correct specification of the functional form for the treatment 
mechanism and iterated conditional expectations. Given that we do not know a priori the 
form of the true probability distribution P0 and the extreme unlikeliness that a simple 
parametric specification will result in a correctly specified model, use of these models will 
most likely result in overly biased estimates which will approach statistical significance with 
probability 1 as sample size increases regardless of whether a treatment effect exists. In 
other words, the use of misspecified parametric models elevates the risk of obtaining 
significant findings even if no true treatment effect is present.
An alternative approach is to use data-adaptive non-parametric methods which reside in a 
much larger statistical model or set of distributions. Examples include gradient boosting 
machines (Friedman 2001, 2002), neural networks (Mc-Culloch and Pitts 1943), and k-
nearest neighbors (Altman 1992). In deciding which method to use, we recommend using 
the ensemble machine learning approach Super Learner, which is based on V-fold cross 
validation and implemented in the R package titled SuperLearner (Polley and van der Laan 
2014). This algorithm takes a user-supplied loss function (chosen to measure performance) 
and a library of algorithms, which can include parametric models as well as non-parametric 
or machine learning algorithms such as those listed above. It uses V-fold cross validation to 
chose the convex combination of these algorithms that performs best on independent data 
(derived from internal data splits). If, as is likely, none of the algorithms in the library 
achieves the rate of convergence one would have with a correctly specified parametric 
model, the Super Learner will still perform asymptotically at least as well as the best 
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algorithm in the library. Otherwise, it achieves an (almost) parametric rate of convergence. 
Furthermore, the derived oracle inequality showing the asymptotic performance also shows 
that the number of candidate algorithms considered in the cross-validation procedure can be 
polynomial in size proportional to the number of observations (van der Laan and Dudoit 
2003; van der Vaart et al. 2006; van der Laan et al. 2007). Therefore, a large number of 
algorithms can be considered, which can grow with the number of observations, without fear 
of hampering the Super Learner’s performance.
To use Super Learning, a loss function must be chosen and a user-specified library provided. 
We chose the non-negative log loss function for its desired steeper risk surface, as this 
function penalizes incorrect probabilities more severely than the more commonly used 
squared error loss. A number of default candidates are included in the SuperLearner package 
that were used here. These include the overall mean, main terms logistic model, step-wise 
regression with AIC (Hoerl and Kennard 1970), generalized additive model (Hastie and 
Tibshirani 1986), Bayesian generalized linear model (Gelman etal. 2008), k-nearest 
neighbors (Altman 1992), LASSO (Tibshirani 1996), ridge regression (Hoerl and Kennard 
1970), neural net (McCulloch and Pitts 1943), multivariate adaptive polynomial spline 
(Friedman 1991), generalized boosted regression model (Friedman 2001, 2002), and support 
vector machine (Boser et al. 1992; Cortes and Vapnik 1995). Additionally, most of the 
algorithms have tuning parameters which can result in better candidate performance. To 
ensure that we were achieving satisfactory performance, we used different tuning parameters 
as additional candidates in the ensemble for the generalized additive models, k-nearest 
neighbors, neural nets, and generalized boosted regression models. We additionally used 4 
user-specific parametric models as candidates in the library. The Super Learner fits were 
constructed using all potential confounders, listed above in Section 3.1 as W and L1(t) for 
each time point t.
Of particular concern to the analyst when deciding on which candidates to include in the 
Super Learner library is the explicit condition that the candidates not be too data adaptive. 
This is because the empirical process conditions for the asymptotic linearity of our estimator 
require that we work within a Donsker class of estimators (van der Laan et al. 2009). Indeed, 
we have seen that algorithms that tend to overfit the empirical data, such as the machine 
learning algorithm random forest, will negatively impact our estimators. We therefore 
excluded these algorithms from our library, though note that such algorithms could still be 
used in a cross-validated parameter estimation approach such as cross-validated targeted 
minimum loss-based estimation (Zheng and van der Laan 2010).
Regarding the pooling of observations across time for the treatment mechanism, one further 
possible option is to use a Super Learner library that is doubled by including estimates from 
both the time stratified and pooled approach. Ensemble weights could then be calculated 
based on the best performing candidate in this larger library and subsequently fed into the 
ltmle package. Consequently, we continue benefiting from the borrowed information at 
different time points and simultaneously protect ourselves from the asymptotic bias of the 
previous approach. We opted not to additionally use the stratified approach, due to the 
computational intensity required of the approach.
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6.1.1 Initial ICE fits—In using non-parametric estimators for the estimation of the ICEs, 
we may potentially disregard the global constraints implied by our statistical model. While 
all the estimators considered here are expected to work well at time t=t* where the outcome 
being modelled is binary, their use at t<t* where the outcome being modelled is known to 
fall within the interval [0,1] can present issues. For example, continuing to treat the outcome 
being modelled as binary may result in programmatic errors since many of the algorithms, 
such as Support Vector Machines or k-nearest neighbors, require that the outcome be 
supplied in classes or as factors. Alternatively, modelling the outcome continuously may 
result in extrapolations with estimates greater than 1 or less than o. As our expectation is 
known to fall within [0,1], this would result in violations of the constraints of the outcome 
being modelled.
For each of the algorithms facing this potential issue, we implemented three approaches 
aimed at ensuring that estimates remained within the constraints. All three were used in the 
Super Learner library, allowing us to objectively compare the performance of each approach. 
We define each of the conditional expectations from eq. [7] to be  such that, for 
example,  and . Let each 
estimator of the conditional expectation within the Super Learner library at time t be denoted 
as  for  where J is the total number of candidates in the Super Learner 
library. We considered
1.
Simply truncating  at both 0 and 1.
2. Taking the logit transformation of the outcome being modelled and truncating at 
a fixed threshold τ (set here to be 0.0001). We then modelled the transformed 
outcome on a continuous scale and took the inverse logit transformation on the 
fitted values.
3. Stratifying the observations by whether they were within the (0,1) open interval 
or within {0,1}, i. e. whether they were continuous within the (0,1) interval or 
dichotomous with only values of 0 or 1. The former were fit on a continuous 
scale after taking the logit transformation, while the latter were modelled as a 
binary outcome.
We emphasize that use of Super Learner for estimation of the treatment mechanisms and 
ICEs provides two important primary benefits. Firstly, its use helps ensure the conditions for 
the asymptotic linearity of our estimator and the corresponding statistical inference are met 
by ensuring the consistent estimation of both the intervention mechanism and the iteratively 
defined conditional expectations. This allows us to establish robust confidence intervals for 
our estimator. Secondly, we gain efficiency in that we get an asymptotically efficient 
estimator if both the treatment mechanisms and ICEs are estimated consistently at fast 
enough rate. Thus, as long as at least one of the library candidates for each of the nuisance 
parameters achieve this optimal rate, our approach will have the lowest variance among all 
regular asymptotically linear estimators. Further, even if we fall short of this goal, the 
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improved estimation of both nuisance parameters offered by Super Learner will generally 
improve finite sample efficiency.
7 Results
Among the 15 clinics implementing the LREC program, a total of 16,513 subjects (31 % 
male) were found to be eligible for the program, of which 16,479 survived past t=0. As we 
only modelled survival up to 450 days, we report figures with follow-up truncated at that 
point. After discretizing the data, these patients contributed a total of 17,668 person-years of 
follow-up to the analyses. From these subjects 1,206 failure events were observed, of which 
1,102 were losses to follow-up and 104 were deaths. All failure events observed at t=1 were 
deaths, since our definition of loss to follow-up required at least 198 days to pass before a 
subject could be lost to follow-up. A small number of subjects (n=128) were censored due to 
transfers to non-LREC clinics, while 3,889 subjects reached the end of study prior to t=4 and 
prior to experiencing a failure event and were administratively censored. Table 3 shows the 
characteristics of the patients conditioning on survival past t=0.
A small proportion of subjects died (42), were lost to follow-up (286), or were censored (60) 
before the LREC program became available. Of the 16,050 subjects who were at some point 
exposed to the program, most (15,294) experienced it by 1-year from baseline. Almost half 
of the study population began follow-up after the LREC program had already initiated, as 
indicated by the large spike in the cumulative incidence at time 0 (Figure 2). A noticeable 
spike was also seen at 1-year after baseline, representing the patients who had their first 
eligibility truncated at 1-year as stated in Section 3.
Patients who were not exposed to the LREC program could not enroll. Furthermore, once 
the LREC program was available, decisions on whether to enroll subjects rested upon the 
treating clinicians or clinical officers. Consequently, only 3,832 subjects were enrolled. As 
expected, subjects who were healthier were more likely to enroll into the LREC program. 
For example, univariate analyses showed that subjects who had higher CD4 counts, were 
receiving ARV, had a WHO stage I or II, were seen in clinics less often, and were not being 
treated for tuberculosis had higher probabilities of enrolling. Additionally, subjects from 
(sub) district hospitals and rural health centers (compared to referral hospitals), with fewer 
missed clinical visits, not on protease-inhibitor based regimen, and who were not pregnant 
also had higher probabilities of enrolling. We note that despite listing non-pregnancy as a 
criteria for being at low risk, a small number of subjects (18) enrolled while pregnant. Figure 
2 shows the cumulative incidence of LREC availability and enrollment. Cumulative 
incidence of enrollment by 90 and 360 days after baseline was 7% (95% CI: 6.3%, 7.1%) 
and 19% (95% CI: 18.8%, 20.1%), respectively.
As stated in Section 3, all patients in our study started follow-up eligible for the LREC 
program, leading to low or no variance in many of the confounders at early time points with 
a skewness towards the healthier values. During follow-up, however, many subjects who did 
not enroll subsequently became less healthy resulting in decreased probabilities of 
subsequent enrollment. Indeed, 3,920 subjects were found to have lost their eligibility prior 
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to enrollment and prior to 1-year, precluding interventions to evaluate a range of different 
enrollment times, as discussed in Section 5.1.2.
Unadjusted analyses using the Kaplan-meier estimator showed overall high probabilities of 
in-care survival among all subjects (Figure 3). Those with immediate LREC availability who 
never enrolled had noticeably lower in-care survival than subjects never experiencing LREC 
availability. For example, at t=4 the proportion of subjects still alive and in care was 0.77 for 
those not enrolling into LREC, compared to 0.93 for the group of subjects never 
experiencing LREC availability and 0.94 for subjects enrolling into LREC immediately. 
Conversely, those with immediate enrollment into the program had the highest survival 
probabilities. Differences in survival probabilities between treatment groups increased with 
time, with the largest differences seen between subjects with immediate enrollment and 
those with LREC availability never enrolling.
The cross-validated risks (using the non-negative log likelihood loss) for the treatment and 
censoring mechanisms are shown in Figure 4 under various models and algorithms. While 
observations at all time points were used in the mechanism fits, our interest is only in 
treatment interventions at t≤3. We therefore only calculated the risks using those time points. 
As expected, the Super Learner fit outperformed all of the candidate estimators in the 
supplied library, as well as the cross-validation selector (i. e. discrete Super Learner, which 
is equivalent to choosing the single algorithm in the library with the lowest cross validated 
risk). Compared to the mean model, which assumes no confounding and does not control for 
any confounders, the Super Learner fits for the LREC availability and end of study 
mechanisms showed an immense decrease in cross-validated risk. This gain was also 
noticeable when compared to the candidate model that only controls for time. The Super 
Learner fit for the enrollment mechanism also outperformed the mean model, though to a 
smaller degree. No noticeable gain was seen in the transfer mechanism, presumably due to 
the extremely low number of transfers observed (218). We did not present the cross-
validated risks for the ICE fits as they are too numerous to describe in detail, though note 
that the gains from using Super Learner were similar to fits for the treatment and censoring 
mechanisms.
Adjustment for potential confounders using the Super Learner fits resulted in relatively 
small updates of the survival curves (Figure 5). Subjects enrolling immediately into the 
LREC program at eligibility continued to have the highest survival probabilities, while those 
with immediate availability not enrolling had the lowest. Tables 4 and 5 show the calculated 
average treatment effects between the different interventions. Confidence intervals and p-
values were calculated based on influence functions. As implied by the survival curves, 
immediate enrollment into the LREC program at eligibility had a beneficial effect relative to 
never having LREC available, while having LREC immediately available and never 
enrolling was adverse. For example, at t=4 the probability of survival for subjects with 
immediate enrollment was 0.93 (95% CI: 0.91, 0.95) and 0.87 (95% CI: 0.86, 0.87) for 
subjects with immediate availability never enrolling. For subjects without LREC availability, 
it was 0.91 (95 % CI: 0.90, 0.92). Similar to the unadjusted estimates, the treatment effects 
increased with time. All estimates after t=1 showed statistical significance.
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It is possible that near positivity violations can have large effects on estimates of our 
parameter. To test for this potential issue, we considered different truncation bounds for our 
treatment probabilities. Specifically, we considered using a bound of 0.001 and using 
untruncated probabilities. No differences were seen in the resulting mean outcome estimates.
8 Discussion
We have presented a comprehensive approach to applying longitudinal targeted minimum 
loss-based estimation to evaluate the impact of the LREC program. Corresponding code for 
the analyses have been uploaded to an online public repository as an R-package at 
www.github.com/tranlm/lrecImpact. The results support a somewhat negligible impact of 
implementation and enrollment, with the lowest survival among patients with immediate 
LREC availability never enrolling and similar survival among the other two interventions 
(Figure 5). Subjects enrolling immediately into the LREC program have almost identical 
survival to subjects never being exposed to the program. While the magnitude of difference 
in survival increased with time, this difference is modest.
We chose 90-day intervals for our time points in the current study, due to the understanding 
that patients would have visits approximately every 3-months. While smaller intervals could 
have been chosen, doing so can reduce the probability of following a given regime of 
interest given observed covariates (i. e. increase the extent of practical positivity violations), 
both by decreasing the probability of availability and enrollment occurring in the first 
interval, and because the probability of never enrolling given observed covariates involves 
taking a cumulative probability of not enrolling given the observed past over many more 
time points. Furthermore, the use of smaller intervals results in more time points, leading to 
higher computational costs. On the other hand, the use of larger intervals leads to discarding 
information in order to preserve time ordering, which can result in a less complete control 
for confounding as well as failure to capture the full causal effect of the intervention. In 
order to preserve time ordering, only covariate and outcome values measured at the end of 
the prior interval are considered possible causes of enrollment and availability in an interval. 
Longer intervals result in more problems with the assumption. We tested whether there was 
an effect in our study by re-running the analyses using 30-day intervals. The resulting 
survival estimates were similar to the ones reported here.
As with all studies, there are limitations that need to be considered. Firstly, it is possible that 
we did not sufficiently adjust for all the potential confounders. For example, the majority of 
subjects who had immediate availability and never enrolled had initial eligibility occur after 
the LREC program had already started. These subjects experiencing incidental eligibility (as 
opposed to prevalent eligibility from those eligible prior to the LREC program initiation) 
may have had factors placing them at higher risk. In addition, in defining our composite 
outcome “dead or lost to follow up” we implicitly assumed that not being seen in clinic for 
198 days is an undesirable outcome reflecting out of care status. In practice, some of these 
patients might represent unreported transfers to care in an alternative clinic. Lastly, our 
analysis considered subjects from the same clinics to be causally independent of each other. 
In specifying our causal model we made a key decision to use an individual level NPSEM 
despite our interest in both an individual and a clinic level exposure variable. Such a 
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formulation assumes that individuals within a given clinic are causally independent, and in 
particular, that the exposure received by one patient does not impact the outcome of another 
(the assumption of no causal interference) (Kline 2011; Tchetgen and VanderWeele 2012). A 
different formulation is possible that uses a hierarchical or clinic level NPSEM and 
corresponding hierarchical identification and analysis. We can think of the corresponding 
experiment as randomizing entire clinics to start the LREC program and within clinics with 
LREC available, randomizing patients to enroll. However, the sample size then becomes 
driven by the number of clinics and identification would require adequate variability in the 
introduction of LREC across clinics (Tchetgen and VanderWeele 2012). We therefore 
pursued an individual level formulation, while noting the limitations of this approach. Future 
research into improved approaches to interference effects in this setting should be 
undertaken.
We end by stating that, while not conducted here, this framework can be easily generalized 
to include dynamic interventions that are dependent upon other covariates. For example, 
there could be interest in intervening to enforce enrollment only on patients who retain 
eligibility during follow-up while exempting patients who do not. Another option to consider 
is the use of marginal structural models to smooth treatment effects across time points, as 
well as availability and enrollment times (Robins 1999a, 1999b; Robins et al. 2000a; 
Petersen et al. 2013) though care should be taken when implementing as the number of 
regimes with available data would be limited. These models allow us to project the true 
underlying dose response curve onto a working parametric model, allowing us to conduct 
inference on a smaller set of parameters. The ltmle package includes a TMLE for causal 
parameters defined as the projection of the survival or failure curve onto user-specified 
parametric models.
In summary we applied the targeted learning roadmap to longitudinal data with a multilevel 
longitudinal treatment of interest to analyze a nurse-based triage system among HIV patients 
in East Africa. This included both definition and identification of our causal parameter. 
Issues with positivity were handled with careful selection of our target causal parameter. 
Nuisance parameters were estimated using Super Learner, a cross-validation ensemble 
algorithm using both parametric and machine learning algorithms. Observations for the 
estimation of the treatment mechanisms were pooled across time points, which aided us in 
estimating the censoring mechanism due to clinical transfers. Various approaches were 
implemented aimed at ensuring the machine learning estimates of the ICEs would respect 
the underlying statistical model. Estimates of survival at each time point were then 
contrasted by their differences and inference derived using the empirical influence functions. 
The results show a somewhat negligible impact of both availability and enrollment in the 
LREC program on in-care survival.
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Appendix. Proof that o and or have equivalent influence functions
We provide a proof here showing that the influence function for the full data o is equivalent 
to the influence function we solve for in our analysis based on the reduced data or=o/L1(K 
+ 1).
Firstly, we know the efficient influence function D(P) for the reduced data or. Our goal is to 
compute the efficient influence function for the full data o for this same parameter (but now 
as a function on a model on o instead of or).
Recall that one can compute an efficient influence function D*(P) by first deriving an 
influence function of any estimator, and then projecting this influence function on the 
tangent space T(P) of the model. D(P) is one such influence function since it is the influence 
function of the TMLE ignoring L1(K + 1). Thus, the desired efficient influence function is 
D*(P)=π(D(P)|T(P)) where π is the projection operator acting onto T(P).
Now, we note that the likelihood of 0 can be factorized as P(L1(K + 1)|Y(K + 1))P(or). Thus, 
the tangent space is the orthogonal sum of the tangent space T1(P) of the first factor P(L1(K 
+ 1)|Y(K + 1)) and the tangent space Tr(P) of P(or). Consequently, π(D(P)|T(P))=π(D(P)|
T1(P)) + π(D(P)|Tr(P)). However, the target parameter is only a function of P(0r), such that 
P(L1(K + 1)|Y(K + 1)) is actually a nuisance parameter. Because the efficient influence 
function is always orthogonal to a nuisance tangent space (i. e. the space of scores one gets 
by varying the nuisance parameters), it is also orthogonal to the tangent space of P(L1|(K 
+ 1)|Y(K + 1)). It follows that D*(P)=π(D(P)|Tr(P)) (i. e. the component in T1(P) is zero).
However, D(P) is the efficient influence function of the target parameter based on or and is 
therefore an element of the tangent space of P(or), so that D(P) is in Tr(P). This results in 
π(D(P)|Tr(P))=D(P), which completes the proof that D*(P)=D(P). That is, the efficient 
influence function of our parameter based on 0r is the same as the efficient influence 
function of our parameter based on o.
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Figure 1. 
Histogram of time from eligibility to LREC program initiation
Tran et al. Page 25
Epidemiol Methods. Author manuscript; available in PMC 2017 July 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Cumulative incidence of LREC availability and enrollment.
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Figure 3. 
Unadjusted Kaplan-Meier survival curves.
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Figure 4. 
Cross-valided risk estimates (using non-negative log-likelihood loss) and 95% confidence 
interval for the treatment and censoring mechanisms. A number of candidates had cross-
validated risks too high to plot in the specified window and consequently are not shown. 
Mean: marginal probability, Time: logistic regression with time variable only, GLM: logistic 
regression with all confounders, AIC step: stepwise regression using the Akaike information 
criterion, GAM: generalized additive model, KNN: k-nearest neighbors, LASSO: least 
absolute shrinkage and selection operator, MARS: multivariate adaptive regression splines, 
Tran et al. Page 28
Epidemiol Methods. Author manuscript; available in PMC 2017 July 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GBM: generalized boosted regression models, SVM: support vector machines, Parametric: 
user specified logistic models using a subset of the confounders
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Figure 5. 
Survival curves adjusting for potential confounders.
Tran et al. Page 30
Epidemiol Methods. Author manuscript; available in PMC 2017 July 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tran et al. Page 31
Table 1
Proportion of visits responsibility assigned between the (a) standard and (b) LREC models of care provision.
Clinical monitoring Standard model LREC model
P/CO Nurse P/CO Nurse
Request CD4/viral load measures All None All None
Monitor/support ART adherence All All 1/3 All
Determine functional status All None 1/3 2/3
Identify/manage ART side effects All None 1/3 2/3
Identify/manage opportunistic infections All None 1/3 2/3
Notes: P, Physician; CO, Clinical Officer.
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Table 2
LREC program clinic characteristics (n=15).
Area No.(%)
Urban 6 (40.0)
Rural 9 (60.0)
Clinic Type No.(%)
Referral hospital 3 (20.0)
(Sub) district hospital 7 (46.7)
Rural health center 5 (33.3)
Patients No.(%)
≤ 500 4 (26.7)
501–1,000 3 (20.0)
1,001–1,500 4 (26.7)
>1,500 4 (26.7)
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Table 3
Characteristics of 16,479 patients at LREC eligibility (conditioning on survival past t=0).
Count (%)
Age (years)
<30 2,793 (17 %)
30–39 7,017 (43 %)
≥40 6,669 (40 %)
Sex
Female 11,441 (69 %)
Male 5,038 (31 %)
CD4 cell count (cells/μL) at ART start
<200 9,754 (59 %)
200–349 2,313 (14 %)
350–499 543 (3 %)
≥500 387 (2 %)
Unknown 3,482 (21 %)
CD4 cell count (cells/μL) at eligibility
<200 0 (0 %)
200–349 10,125 (61 %)
350–499 4,016 (24 %)
≥500 2,334 (14 %)
Unknown 4 (0 %)
Pl-based ARV regimen
No 15,600 (95 %)
Yes 879 (5 %)
Max WHO stage prior to ARV start
I/II 7,696 (47 %)
III/IV 8,373 (51 %)
Unknown 410 (2 %)
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